Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-positive Early Breast Cancer
NCT06718335Phase 2Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of pyrotinib in HER2-positive breast cancer (3 arms). Primary endpoint: Event Free Survival at 3 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06718335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718335.